Pre-referral Rectal Artesunate Treatment by Community-Based Treatment Providers in Ghana, Guinea-Bissau, Tanzania, and Uganda (Study 18): A Cluster-Randomized Trial by Warsame, M et al.
Clinical Infectious Diseases
S U P P L E M E N T A R T I C L E
Pre-referral Rectal Artesunate Treatment by Community-
Based Treatment Providers in Ghana, Guinea-Bissau,
Tanzania, and Uganda (Study 18): A Cluster-Randomized
Trial
Marian Warsame,1,a Margaret Gyapong,2 Betty Mpeka,3 Amabelia Rodrigues,4 Jan Singlovic,5 Abdel Babiker,6 Edison Mworozi,7 Irene Agyepong,8 Evelyn Ansah,9
Robert Azairwe,10 Sidu Biai,4 Fred Binka,11 Peter Folb,12 John Gyapong,13 Omari Kimbute,14 Zena Machinda,15 Andrew Kitua,16 Tom Lutalo,17 Melkzedik Majaha,18
Jao Mamadu,4 Zakayo Mrango,14 Max Petzold,19 Joseph Rujumba,20 Isabela Ribeiro,21 and Melba Gomes5; for the Study 18 Research Groupb
1Division of International Health, Karolinska Institutet, Stockholm, Sweden; 2Dodowa Health Research Centre, Ghana; 3Malaria Consortium, Kampala, Uganda; 4Projecto de Saude de Bandim, Guinea-Bissau;
5Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland; 6Medical Research Council Clinical Trials Unit, London, United Kingdom; 7Makerere
University Medical School, Kampala, Uganda; 8Greater Accra Regional Health Directorate, 9Dangme West District Health Directorate, Dodowa, Ghana; 10National Malaria Control Programme, World Health
Organization Uganda Country Office, Kampala; 11University of Health and Allied Sciences, Ho, Ghana; 12Medical Research Council, Tygerberg, South Africa; 13University of Ghana, Accra; 14National Institute for
Medical Research, Dar-es-Salaam; 15St Augustine University of Tanzania, Mwanza; 16Preparedness and Response Project, Lugogo House, Kampala, Uganda; 17Rakai Health Sciences Program, Rakai Project
Centre, Entebbe, Uganda; 18National Institute for Medical Research, Gonja Field Station, Tanzania; 19Centre for Applied Biostatistics, Sahlgrenska Academy, University of Gothenburg, Sweden; 20College of
Health Sciences, Makerere University, Kampala, Uganda; and 21Drugs for Neglected Diseases, Geneva, Switzerland
Background. If malaria patients who cannot be treated orally are several hours from facilities for injections, rectal artesunate
prior to hospital referral can prevent death and disability. The goal is to reduce death from malaria by having rectal artesunate treat-
ment available and used. How best to do this remains unknown.
Methods. Villages remote from a health facility were randomized to different community-based treatment providers trained to
provide rectal artesunate in Ghana, Guinea-Bissau, Tanzania, and Uganda. Prereferral rectal artesunate treatment was provided in
272 villages: 109 through community-based health workers (CHWs), 112 via trained mothers (MUMs), 25 via trained traditional
healers (THs), and 26 through trained community-chosen personnel (COMs); episodes eligible for rectal artesunate were established
through regular household surveys of febrile illnesses recording symptoms eligible for prereferral treatment. Differences in treatment
coverage with rectal artesunate in children aged <5 years in MUM vs CHW (standard-of-care) villages were assessed using the odds
ratio (OR); the predictive probability of treatment was derived from a logistic regression analysis, adjusting for heterogeneity between
clusters (villages) using random effects.
Results. Over 19 months, 54 013 children had 102 504 febrile episodes, of which 32% (31 817 episodes) had symptoms eligible
for prereferral therapy; 14% (4460) children received treatment. Episodes with altered consciousness, coma, or convulsions constituted
36.6% of all episodes in treated children. The overall OR of treatment between MUM vs CHW villages, adjusting for country, was
1.84 (95% conﬁdence interval [CI], 1.20–2.83; P = .005). Adjusting for heterogeneity, this translated into a 1.67 higher average probability
of a child being treated in MUM vs CHW villages. Referral compliance was 81% and signiﬁcantly higher with CHWs vs MUMs: 87%
vs 82% (risk ratio [RR], 1.1 [95% CI, 1.0–1.1]; P < .0001). There were more deaths in the TH cluster than elsewhere (RR, 2.7 [95% CI, 1.4–
5.6]; P = .0040).
Conclusions. Prereferral episodes were almost one-third of all febrile episodes. More than one-third of patients treated had convul-
sions, altered consciousness, or coma.Mothers were effective in treating patients, and achieved higher coverage than other providers. Treat-
ment access was low.
Clinical Trials Registration. ISRCTN58046240.
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Prompt, effective malaria treatment prevents death. For severe
malaria, artesunate is the treatment of choice. Given injectably,
artesunate saves more lives than quinine [1, 2]; given rectally,
prior to hospital referral, artesunate prevents both death and
disability [3].
Prereferral rectal artesunate adds to an arsenal of inexpensive
case management interventions for use in high-mortality set-
tings to reduce illness severity, mortality, and disability. Given
appropriately, it reinforces a continuum of care between the
aPresent affiliation: Global Malaria Programme, World Health Organization, Geneva,
Switzerland.
bMembers of the Study 18 Research Group are listed in the Notes.
Correspondence: M. Warsame, World Health Organization, 1211 Avenue Appia, Geneva 27,
Switzerland (warsamem@who.int).
Clinical Infectious Diseases® 2016;63(S5):S312–21
© 2016 World Health Organization; licensee Oxford Journals. This is an open access article
distributed under the terms of the Creative Commons Attribution IGO License (http://
creativecommons.org/licenses/by/3.0/igo/legalcode), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited. In
any reproduction of this article there should not be any suggestion that WHO or this article
endorse any specific organisation or products. The use of the WHO logo is not permitted.
This notice should be preserved along with the article’s original URL. DOI: 10.1093/cid/ciw631
S312 • CID 2016:63 (Suppl 5) • Warsame et al
home and health facility [4]. It is recommended by the World
Health Organization (WHO) [5]and has been added to the com-
munity component of Integrated Management of Childhood Ill-
ness (IMCI) algorithm which supports early recognition,
assessment, treatment, and referral of patients with danger
signs in the community [6]. In this algorithm, rectal artesunate
treatment is required prior to referral when the child has general
danger signs indicative of inability to eat, drink, or suck (non per
os [NPO]) including: repeated vomiting; recent convulsions; leth-
argy; or altered/lost consciousness. Facility management after
treatment is necessary both to diagnose other infections that
might be the cause of life-threatening symptoms and to complete
malaria treatment.
The main objective now is to maximize coverage. Treatments
only save life if available, accessed, and used. Rectal artesunate
takes 4–6 hours to reduce parasitemia. Therefore, the main ther-
apeutic beneﬁt of rectal artesunate is obtained by those who may
need several hours to reach a referral facility. During this time the
treatment can affect progression of the disease substantially, and
reduce the risk of death or permanent disability. Geographical
distance from services is a risk factor for death [7]. Even when
services are available, logistics and costs anticipated—transport,
medications, food, time lost—may prohibit timely access
[8–10]. In consequence, many deaths occur without any contact
with health services [11]. If used with a rapid diagnostic test, the
absolute beneﬁt of treatment increases in relation to the propor-
tion of children with prereferral episodes caused by malaria in
the community. The higher the proportion of malaria prereferral
episodes, the more important treatment coverage becomes to
achieve mortality and disability reduction. Estimates of the bur-
den of prereferral episodes, whether or not caused by malaria, are
not generally available because epidemiological data are not col-
lected on prereferral episodes and, by deﬁnition, hospital data ex-
clude children who do not reach the facility [12, 13].
Mothers [14, 15] and other community health workers
(CHWs) have demonstrated their ability to treat uncomplicated
malaria [16, 17], and community-directed treatment programs
have been used successfully for treatment access [18]. Traditional
birth attendants have been taught tomanage pneumonia and neo-
natal sepsis [19–21], and these and other traditional practitioners
are often the ﬁrst recourse for management of severe disease [22–
25].We anticipated that these types of community-based person-
nel could be trained to provide rectal artesunate and refer patients
for further management, but their performance in increasing ac-
cess, following up patients, or reinforcing compliance might vary.
We implemented a cluster-randomized study in remote rural
villages in Ghana, Guinea-Bissau, Tanzania, and Uganda to obtain
evidence on what level of coverage is achievable in practice. Our
design enabled us to establish which type of treatment providers
were best in reaching patients in need and to provide evidence
on the burden of prereferral episodes in children in remote villag-
es. A cluster design responded to the need to measure coverage by
community-based treatment providers who are normally respon-
sible for a geographical catchment area.
METHODS
Study Area and Population
The intervention was implemented in West-Dangbe district in
Ghana; Oio and Biombo districts in Guinea-Bissau; Mubende
and Mityana districts in Uganda; and Mtwara district in
Tanzania between 2005 and 2008 after assessing treatment-
seeking behavior for severe illness [26–28].
Study Design, Randomization, and Masking
Villages without other research interventions, and at least 5 km
from the nearest health facility, with at least 400 preschool
children and a stable population were eligible for randomiza-
tion. Each of 346 eligible villages were listed and randomized
to different community-based treatment providers (hereinafter
called treatment providers) by country, from a computer-
generated random allocation sequence (www.randomization.
com), concealed until assigned; 42 villages did not implement:
civil war (34 villages), inability to conduct surveillance (5 villag-
es), 2 wrong randomizations, and 1 refusal. All remaining vil-
lages provided approval for the study. Twenty-eight villages
were excluded from the analysis because of incomplete surveys
during the implementation period (Figure 1).
All countries chose to compare coverage achieved by CHWs vs
mothers (MUM). In Guinea-Bissau and Ghana, an additional
treatment provider was chosen: traditional healers (TH) in
Guinea-Bissau and a “community chosen”mix of treatment pro-
viders (COM) in Ghana. Treatment coverage and relative treat-
ment rates were the primary endpoints, with referral completion
rates and adverse outcomes as secondary endpoints (measured
individually and by cluster).
Treatment providers knew that their performance would be
checked but were not informed that there would be routine sur-
veys of febrile and prereferral episodes (described below) as part
of the study or that the number of children they treated was to
be monitored. Patients were informed about the drug, its prior
history, and where and when to obtain it, but were not aware of
allocation (ie, type of cluster). Study personnel were unaware of
cluster performance except for verifying data during the period
of implementation—deﬁned as the exact period within which
treatment and surveillance occurred—from drug provision
until drug withdrawal, for each village.
Coverage Numerator: Provision of Treatment
Selection of Treatment Providers
In villages randomized to CHWs, existing CHWs were identi-
ﬁed and trained; if not operational, the local procedure for
choosing CHWs was applied. Other treatment providers
(MUM, TH, COM) were chosen by their communities but
had to meet other characteristics (eg, MUMs had to be mothers
of young children, THs were practicing traditional healers). All
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were resident in their village, numerate, generally considered re-
sponsible and trustworthy, and willing to provide prereferral
treatment at any time. None were paid.
In Uganda it was established, postrandomization, that
CHWs were not operational in the study villages despite an
ofﬁcial strategy of having CHWs in all villages; thus only in
Uganda, selection and training of CHWs and MUMs occurred
in parallel. About 3 months after both became operational,
a government policy speciﬁed that all CHWs should treat
suspected malaria with oral prepackaged ﬁxed-combination
therapy (sulfadoxine-pyrimethamine + chloroquine; HOMA-
PAK); this affected 68 villages (31 CHW villages, 37 MUM
villages).
Training Treatment Providers and Sensitizing Communities
Community posters and pictorial training materials for treat-
ment providers (ﬂipcharts, calendars, case report forms
[CRFs]) emphasizing early treatment of suspected severe malar-
ia were developed by a graphic designer. Materials were in the
local dialect and emphasized treatment age, signs and symp-
toms, rectal administration, dose, and the importance of referral
to health facilities. Materials were tested for comprehension
before use.
Treatment providers in each country were trained together
(196 in Ghana, 125 in Guinea-Bissau, 208 in Tanzania, 158 in
Uganda) to assess, treat, refer, and follow up patients. The goal
was identical training for each treatment provider in a country.
Providers who failed certiﬁcation were retrained or replaced.
The number of children who were treated, referred, and fol-
lowed up was documented. The training curriculum, developed
with health authorities, included information on severe malaria,
artesunate, symptoms eligible for treatment clinical assessment
of patients, informed consent procedures, completion of forms,
suppository administration, referral, and follow-up of patients
(http://video.who.int/streaming/tdr/WHO-TRA_Malaria_rectal_
artesunate_19SEPT2012_en.wmv) [29]. Tanzania had practical
sessions on suppository insertion at facilities. Sachets with an
artesunate suppository (Abbott artesunate, Scherer capsules,
Scanpharm packaging) and coded labels (to be peeled and
stuck on the enrollment form) were provided with each dose
to each treatment provider together with other materials (sta-
tionery, calendars, notebooks).
Figure 1. Trial profile of clusters and participants.
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Treatment Eligibility and Referral
Treatment providers assessed patients for eligibility (inability to
eat, drink, or suck; repeated convulsions; lethargy/weakness
preventing oral medication; repeated vomiting; altered con-
sciousness or coma), obtained individual informed consent
from guardians (signed or witnessed and ﬁngerprinted), com-
pleted a pictorial treatment form, treated, and referred patients
to the nearest health facility. Parasitological examination was
not undertaken before treatment [30]. Reinsertion of a fresh
suppository was allowed if the ﬁrst was documented as expelled
within 30 minutes. Treated patients were to be followed up
within 3–15 days to record outcome and establish compliance
with referral advice; patients still unwell at follow-up were to
be re-referred again to health facilities. At the referral facility,
staff were oriented about the study, advised on reasons for
prioritizing children with a referral note, and provided with a
facility form to track progress.
Coverage Denominator: Morbidity and Mortality Surveillance
Episodes needing prereferral artesunate treatment constituted
the denominator in calculations of treatment coverage. Approx-
imately every month in each village, all households with chil-
dren aged <5 years were to be visited (3 attempted interviews)
to determine and document whether a child from the house-
hold had been febrile since the last visit. Among febrile children,
symptoms eligible for rectal artesunate treatment (prereferral
episodes) and episode outcomes were recorded. In Ghana and
Tanzania, parental actions taken for each prereferral episode
were also recorded. Deaths were veriﬁed. Surveillance surveys
were executed independently by different teams, without
knowledge of cluster allocation. Surveys began in each village
after the ﬁrst month of treatment was provided in a village
and concluded after drugs were withdrawn.
Implementation
In each village, implementation began after trained village treat-
ment providers were provided with drugs. Their location and
responsibilities in the village for the following 18 months
were introduced and approved, usually at a public village
meeting; the ﬁrst village began implementation in 2005. After
the ﬁrst month of correcting CRF completion mistakes,
treatment provider performance was supported and observed
without interference, except for regular visits when supplies
were replenished, drug inventory was scrupulously checked
against treatment CRFs, survey registers were collected, and
deaths, sequelae, and losses to follow-up were veriﬁed. Compli-
ance with referral advice posttreatment was conﬁrmed by a
completed facility form and a stamped referral note and patient
follow-up. When villages approached their 18th month of
operation, visits were made to each village to complete the for-
malities of study closure, including withdrawing medication,
consolidating and verifying drug accountability, and complet-
ing ﬁnal household surveys. No instances of drug misuse were
identiﬁed in drug reconciliation. Study closure for each village
took place over several weeks while inconsistencies in the
surveillance and treatment databases were resolved. The trial
was monitored.
Sample Size Calculations
The required sample size was based on anticipated treatment
coverage and determined by assuming that the average popula-
tion of each village would contain about 1600 persons, of whom
20% were expected to be aged <5 years. We anticipated 4 epi-
sodes of febrile illness per child during a minimum period of
18 months and (in the absence of data) expected 30% of epi-
sodes to be eligible for prereferral treatment, so that on average
about 384 eligible episodes were predicted to be observed in
each village during the study period. The average treatment cov-
erage of CHWs was estimated to be 45% with an intracluster
coefﬁcient between villages of 0·25. Under these assumptions,
a total of 27 villages per arm would provide 80% power to detect
an increase of 10% (from 45% to 55%) in average treatment
coverage using a 2-sided t test with α = .05. A total of 36 villages
per arm would provide 90% power to detect the same difference.
We therefore planned to randomize between 27 and 36 villages
to each type of treatment provider in each country.
Statistical Methods
In 3 countries (Ghana, Guinea-Bissau, Uganda), 28 villages (10
CHW, 14 MUM, 1 TH, 3 COM) had incomplete data from
household surveys (treated episodes exceeded reported number
of episodes needing treatment), and the differences between re-
ported and treated cases could not be reliably reconstructed ret-
rospectively; these villages were excluded from the primary
analyses (Figure 1). Contributing villages (109 CHW, 112
MUM, 25 TH, 26 COM) were analyzed by randomized alloca-
tion. Treated, nonresident children were excluded from all cal-
culations. Descriptive statistics were used to compare the
annualized risks of events (reported fevers, prereferral episodes)
during the intervention period per child-year, by cluster and
country. The distribution of events were compared by χ2 tests
with 2-sided P values.
Primary Analysis
The primary objective was to compare the randomized arms in
terms of treatment coverage with rectal artesunate in children
aged <5 years with symptoms eligible for treatment (NPO).
The primary comparison was MUM villages vs CHW (stan-
dard-of-care) villages. The coverage difference between clusters
was assessed in terms of the odds ratio (OR) and the predictive
probability of treatment derived from a logistic regression anal-
ysis, adjusting for heterogeneity between clusters (villages)
using random effects. The marginal treatment coverage (and
its standard error) for each arm was calculated as the average
of the predicted probability of treatment for each NPO child
(derived from the logistic model). The treatment coverage
ratio (ratio of the marginal treatment coverage [for MUM
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relative to CHW]) and its conﬁdence interval (CI) were derived
using the δ method.
We also performed 2 sensitivity analyses for the primary
outcome—at the child level and at the cluster level. For the
child-level analysis, we used ordinary logistic regression but
with robust estimation of standard errors that take clustering
by village into account. For the cluster-level analysis, we used
a weighted linear regression model of the empirical log-odds
of treatment with weights proportional to the inverse of the var-
iance of the log-odds in each village. For each village, the empir-
ic log-odds was calculated as the natural logarithm of the ratio
of the number of NPO children treated (a) to the number of
those not treated (b) with variance (1/a + 1/b). For villages
with a = 0 or b = 0, 0.5 was added to both a and b. All analyses
were carried out using Stata software, versions 13 and 14 [31].
RESULTS
Implementation took place over an average of 19 months.
Figure 1 shows the trial organization and the contribution of
24 734 households and 54 013 children <5 years of age to the
trial and morbidity, by cluster.
Combining the 4 countries, a total of 102 504 febrile episodes
were reported, giving an incidence density rate of about 2.4 fe-
brile episodes per child per year (Table 1). There were compa-
rable risks of febrile episodes by cluster, but not by country,
ranging from 3.3 episodes per child-year in Tanzania to 1.1
per child-year in Ghana. In these areas not immediately served
by facilities, the prevalence of prereferral episodes averaged 31%
(31 817/ 102 504) of all fevers, varying from 26% to 41% among
the countries. The average incidence density rate was 0.7
prereferral episodes per child-year exposed, and the highest
prevalence of fevers and prereferral episodes was in Tanzania.
Rectal artesunate treatment was provided to 14% of children
with prereferral episodes (4460 treated out of 31 817 reported
episodes). Table 2 subdivides treated prereferral episodes by
type and by cluster. Because of their higher risk for death, epi-
sodes with altered consciousness, coma, or convulsions, hereaf-
ter called central nervous system (CNS) episodes, are separated
from episodes with other symptoms (weakness, lethargy, re-
peated vomiting). CNS episodes were 36.6% of all prereferral
episodes in children seeking treatment, excluding 39 episodes
(0.8%) where accompanying symptoms were not recorded.
There were signiﬁcantly higher episodes with CNS symptoms
coming for treatment to CHW vs any other cluster: CHW
(41.5%) vs MUM (35.5%): risk ratio (RR), 1.16 (95% CI,
1.07–1.26; P < .0003); CHW vs TH (26.8%): RR, 1.54, (95%
CI, 1.18–2.02; P < .0005); CHW vs COM (28.6%): RR, 1.40
(95% CI, 1.18–1.66; P < .0001).
Completion of referral advice at a facility was documented
at follow-up within a median of 6 days for 98.6% of patients.
Overall, 81.4% of patients proceeded to facilities for further
care but referral completion was better with CHWs vs
MUMs: 85.7% vs 80.4% (RR, 1.06 [95% CI, 1.03–1.09];
P < .0001) or CHW and MUM combined vs COM and TH vil-
lages combined: 83.6% vs 75.2% (RR, 1.11 [95% CI, 1.06–1.17];
P < .0001). The death rate was higher in the TH cluster than
elsewhere (RR, 2.7 [95% CI, 1.35–5.58]; P = 0040).
The primary objective was to predict the likelihood of a child
being treated by type of treatment provider. Results are given in
Table 3, adjusting for heterogeneity between villages by a ran-
dom effect for cluster in logistic regression analysis. The results
Table 1. Total Number of Febrile Cases and Prereferral Episodes Reported in Surveillance, and Annualized Risks During the Intervention Period per Child-
Year, by Cluster and Country
Type of Episodes
Control Experimental Treatment Providers
Total
Community Health
Workers Mothers Traditional Healers Community Mix
No.
Risk per Child
per Year No.
Risk per Child
per Year No.
Risk per Child
per Year No.
Risk per Child
per Year No.
Risk per Child
per Year
Febrile episodes (without danger signs)
Guinea-Bissau 5743 2.09 3119 1.74 4129 1.44 12 991 1.8
Ghana 1571 1.19 1632 1.07 1826 1.17 5029 1.1
Tanzania 28 047 3.39 30 358 3.28 58 405 3.3
Uganda 10 897 1.94 15 182 1.88 26 079 1.9
Total 46 258 2.58 50 291 2.44 4129 1.44 1826 1.17 102 504 2.4
Prereferral episodes (with danger signs, NPO)
Guinea-Bissau 2315 0.84 1508 0.84 1614 0.56 5437 0.7
Ghana 878 0.67 943 0.62 1145 0.73 2966 0.7
Tanzania 8114 0.98 9675 1.05 17 789 1.0
Uganda 3049 0.54 2576 0.32 5625 0.4
Total 14 356 0.80 14 702 0.71 1614 0.56 1145 0.73 31 817 0.7
Abbreviation: NPO, non per os.
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vary by country, with no difference in the predicted probability
of a child being treated in a MUM vs CHW cluster in Guinea-
Bissau or Uganda but double the probability of being treated in
Tanzania or Ghana. The overall ORs and CIs reﬂect these
results: an OR of 1.84 (95% CI, 1.20–2.83; P = .005) translates
into a 1.67 higher overall predicted probability of a child
being treated in MUM vs CHW clusters.
Figures 2 and 3 provide this information diagrammatically.
Figure 2 presents the odds of treatment in MUM vs CHW clus-
ters adjusting for differences between villages, and Figure 3 pro-
vides the predicted probability ratios of coverage for each
country and shows the higher overall coverage in MUM vs
CHW clusters.
DISCUSSION
Uniformly trained to administer an artesunate suppository in
inaccessible villages on the basis of a clinical assessment of
danger signs in children, 687 different types of voluntary
treatment providers successfully assessed, treated, referred,
and followed up treated patients in their communities. The
combined data comparing their performance in reaching
and treating children in 272 villages provide strong evidence
that mothers (MUMs) had a 1.67 higher likelihood of admin-
istering prereferral artesunate to children in need of treat-
ment compared with CHWs. This result was hoped for,
and underpinned the trial. Despite evidence that mothers
could be trained to assess and treat young, sick children in
other studies [14, 15], and a proliferation of community pro-
grams using CHWs to deliver a wide range of services, no
study has convincingly compared performance or treatment
access achieved by different types of providers vs each other
or vs mothers [32, 33].
A few hours’ delay in malaria can be fatal in a young child,
and referral is necessary to complete management and diagnose
other conditions. Our earlier trial of rectal artesunate plus refer-
ral had extremely high referral completion rates (90%–99%) and
Table 2. Episodes Treated With Prereferral Rectal Artesunate, All Countries
Type of Episodes
Control
Experimental Treatment Providers
TotalCommunity Health Workers Mothers Traditional Healers Community Mix
Treated episodes, by symptoma
Without CNS symptomsa 855 (58.2) 1569 (63.7) 111 (72.6) 253 (67.7) 2788 (62.5)
CNS symptomsa 609 (41.5) 876 (35.5) 41 (26.8) 107 (28.6) 1633 (36.6)
Not documented 5 (0.3) 19 (0.8) 1 (0.6) 14 (3.7) 39 (0.9)
Compliance with referral advice
Went to facility 1259 (85.7) 1982 (80.4) 97 (63.4) 294 (78.6) 3632 (81.4)
No compliance 192 (13.1) 443 (18.0) 53 (34.6) 76 (20.3) 764 (17.2)
Used alternative care 18 (1.2) 39 (1.6) 3 (2.0) 4 (1.1) 64 (1.4)
Deaths among treated episodes
Alive 1413 (96.2) 2384 (96.8) 144 (94.1) 353 (94.4) 4294 (96.3)
Died 37 (2.5) 41 (1.6) 8 (5.2) 3 (0.8) 89 (2.0)
Lost to follow-up 19 (1.3) 39 (1.6) 1 (0.7) 18 (4.8) 77 (1.7)
Total, No. 1469 2464 153 374 4460
Data are presented as No. (%).
Abbreviation: CNS, central nervous system.
a CNS symptoms are defined as altered consciousness, coma, or convulsions.
Table 3. Likelihood of Being Treated, Community Health Workers Versus
Mother Cluster: Logistic Regression Results, Adjusting for Heterogeneity
Between Villages by a Random Effect for Cluster
Country
&
Cluster
Odds of Being Treated Predictive Probability of Treatment
Odds Ratio (95% CI); P Value Ratio (95% CI); P Value
Guinea-Bissau
MUM 0.06 (.02–.19) 0.06 (.02–.17)
CHW 0.05 (.02–.15) 0.05 (.02–.14)
Ratio 1.17 (.23–5.85); .8523 1.16 (.25–5.35); .8522
Ghana
MUM 0.73 (.39–1.36) 0.42 (.29–.60)
CHW 0.27 (.14–.52) 0.22 (.13–.36)
Ratio 2.66 (1.09–6.52); .0321 1.96 (1.06–3.65); .0333
Tanzania
MUM 0.17 (.12–.24) 0.15 (.11–.20)
CHW 0.08 (.06–.11) 0.07 (.05–.10)
Ratio 2.19 (1.34–3.57); .0017 2.02 (1.30–3.12); .0017
Uganda
MUM 0.32 (.18–.55) 0.24 (.16–.37)
CHW 0.23 (.13–.42) 0.19 (.12–.31)
Ratio 1.37 (.60–3.10); .4551 1.28 (.67–2.44); .4559
Overall, adjusted for country
MUM 0.22 (.16–.29) 0.17 (.13–.22)
CHW 0.12 (.09–.16) 0.10 (.08–.13)
Ratio 1.84 (1.20–2.83); .0050 1.67 (1.17–2.38); .0051
Abbreviations: CHW, community health worker; CI, confidence interval; MUM, mother.
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very rapid transit to the referral facility [3]. Indeed, the beneﬁt
was statistically deﬁnite only among patients who needed time
to reach a facility because during this period artesunate could
halt parasite proliferation and sequestration and confer beneﬁt.
Such exceptionally good referral completion rates raised con-
cerns that compliance might not be achievable routinely [34].
Sharing the same concerns, we provided referral notes in this
study to motivate patients to complete the referral process, assist
facility triage, and expedite curative treatment of children whose
symptoms had resolved. Four of 5 patients followed referral ad-
vice (81%) in this study, and similar levels of referral completion
have now been documented elsewhere [13] and in countries
with a high malaria burden [35, 36]. A small proportion of pa-
tients defaulted referral, and parents of these children often re-
ported taking no further posttreatment action because the child
had improved. Others came too late for treatment to have much
chance of providing any material beneﬁt and died en route to
hospital [36, 37]. In future work, this ﬁnding needs to be
Figure 2. Coverage: odds ratios (ORs) and 95% confidence intervals (CIs) for treatment, mother (MUM) vs community health worker (CHW) clusters.
Figure 3. Coverage: adjusted predicted probability ratio of treatment (odds ratios [ORs] and confidence intervals [CIs]), mother (MUM) vs community health worker (CHW)
clusters.
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emphasized; treatment can only beneﬁt patients if they come
early enough for it to be of value.
Prompt diagnosis and treatment is essential to prevent fatal
malaria, reduce the numbers of patients who can transmit ma-
laria, and rapidly identify patients with other causes of illness.
Among the 4460 patients who declared their inability to control
an infection and were treated with prereferral rectal artesunate,
a well-tested clinical algorithm was used by treatment providers
to verify eligibility for treatment, but parasitology was not un-
dertaken so determination of the pathogen is uncertain. Malaria
treatment guidelines specify that an artesunate suppository
should be administered to children as soon as a presumptive
diagnosis of severe malaria is made because a high risk of
death warrants emergency treatment [5]. Prereferral rectal arte-
sunate treatment reduces the risk of death of patients with ma-
laria. However, not all children with danger signs had malaria
and the survival of those without malaria, or with incidental
malaria and another cause of illness, would depend on speed
of diagnosis of alternative infections and management of com-
plications at the facility [38]. In our previous trial, 74% of pa-
tients had positive blood slides [3], and a more recent study
has shown 82% positivity [35]. As RDTs become available
and used routinely, they will reinforce prereferral treatment
and reveal the number of patients with danger signs for
whom malaria is negative.
Nobody knows how many childhood febrile episodes have
danger signs that require prereferral treatment. Prospective,
population-based data on prereferral episodes are simply not
available, and the regularity with which surveillance is under-
taken determines the number of clinical events detected [39].
Monthly surveys—a trade-off between what is practical and
reliable—detects fewer clinical events than weekly surveys
[40]. The prevalence burden during the period of the study
was high. This very large study prospectively following up fevers
over 19 months indicates that close to one-third of febrile epi-
sodes are apparently accompanied by danger signs. For those
who came for treatment, an average of 37% had symptoms of
repeated convulsions, altered consciousness, or coma. The
study was conducted between 2005 and 2008–2009 when bed-
net usage was very low and neither ACTs nor RDTs were widely
available [41]. National policy changed to ACTs in 2005 in
Ghana, in 2006 in Uganda and Tanzania, and in 2007 in
Guinea-Bissau. Ghana and Uganda had ACTs for uncomplicat-
ed malaria at facilities but not in the community, and ﬁrst-line
antimalarial treatment available in Tanzania and Guinea-Bissau
in the study areas was sulfadoxine-pyrimethamine and chloro-
quine, respectively, throughout the study. The lack of effective
treatment and limited bednet usage in the countries undoubtedly
contributed to the morbidity reported. Artemisinin combination
treatment for malaria has since increased and transmission de-
clines have been reported in many African countries. As evident
from our recent study in high malaria prevalence countries, the
ideal is that oral artemisinin combination treatment be used in
time to prevent uncomplicated malaria episodes from becoming
severe [35]. Even in these circumstances there will still be some
children who can no longer be treated orally and are in need of
prereferral rectal artesunate.
Prereferral rectal artesunate availability through trained
treatment providers residing in communities of patients should
widen access to diagnosis and accelerate treatment of malaria-
positive patients. However, the availability of the intervention
for patients distant from facilities did not, on its own, generate
adequate demand and use. Given the opportunity for immedi-
ate access to a life-saving treatment when a child became acute-
ly ill, only 14% accessed treatment in their communities.
Although this low level of coverage could have been caused
by insufﬁcient knowledge about the availability and relevance
of the intervention, it is also possible that there were too few
treatment providers (ie, that they were unavailable when need-
ed) or that morbidity exceeded the ability of few treatment
providers per village to cope. Many guardians probably did
not go to community-based health providers for a variety of
reasons, from anticipated costs to perceptions that the child
was not sufﬁciently ill [42]. Providers were not remunerated,
and this might have reduced their availability at their treatment
posts as they would be engaged in other income-earning activ-
ities. Although incentives might have improved coverage, pay-
ment would also have changed the nature of the intervention,
irreversibly changed expectations, and prejudiced the approach
for scale-up in countries not planning to remunerate commu-
nity health workers during routine deployment of the
intervention.
Knowledge about the importance of this intervention has
changed in the past 5 years. Prereferral rectal artesunate and
RDTs have been included in community IMCI guidelines [6]
and with guidance by WHO and UNICEF, national treatment
guidelines have changed to incorporate both; several national
government strategies have evolved to incorporate integrated
community case management, to screen and treat patients who
can safely be managed in the community and refer those who
should obtain specialized care [43, 44]. Complementing these
efforts, the Global Fund (which ﬁnances most malaria control
efforts) has begun encouraging country applicants to include
community system–strengthening initiatives in proposals wher-
ever relevant to bridge the gap between the formal health system
and the community. In consequence, increasing data are becom-
ing available on country upscaling efforts [13, 35, 36]. Skills and
competence of the CHWs to manage high-risk patients through
training and supervision are being developed. Several African
countries now pay community health workers or combine ﬁnan-
cial and nonﬁnancial incentives; these approaches are likely to
ensure retention and timely availability of trained CHWs for
emergency management of malaria using prereferral rectal
artesunate.
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